
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is well-positioned in the oncology biopharmaceutical market with its top-prescribed drug, BRUKINSA, and a strong financial foundation. This, along with their pipeline of promising candidates, makes the company a leader in CLL treatment and also positions them for potential growth in solid tumor treatments. The company's focus on diversity and ethical standards also adds to its long-term value creation potential.
Bears say
BeOne Medicines is a holding company operating in the pharmaceutical products segment, generating the majority of its revenue from the sale of its oncology-focused biopharmaceutical products, including BRUKINSA, sonrotoclax, and BTK-CDAC. However, their projected revenue growth of 32% in 2025 is insufficient to offset the combined 10-year royalty revenue of only ~$1.3B for Imdelltra, and they face challenges in comparison with other drugs in development and defending their market exclusivity. Furthermore, they face material sustainability issues and potential geopolitical risks, and their high cash burn on the pipeline may not lead to marketable drugs, which could result in substantial downside if Brukinsa, their key revenue driver, faces any pressure.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares